|NIH3T3 Cell Lines Carrying c-Met Mutations Including G3906A, G3522A, G3810T, T3936C, T3936G, T3997C, C3528T, C3564G, C3831G, A3529T, and T3640C|
Description of Invention:
MET is over expressed in a variety of cancers including hereditary papillary renal cell carcinoma and non-small cell lung cancer. These cell lines carry naturally-occurring Met mutations and were derived from the germline of patients with hereditary papillary renal cell carcinoma. These cell lines can be used as drug discovery research reagents.
These cell lines were described in part in Schmidt et al., “Novel mutations of the MET proto-oncogene in papillary renal carcinomas,” Oncogene (1999) 18:2343-2350, and Jeffers et al., “Activating mutations for the met tyrosine kinase receptor in human cancer,” PNAS (1997) 94:11445-11450.
Laura S Schmidt (NCI)
HHS, Reference No. E-327-2005/0
In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
For Licensing Information Please Contact:
Sabarni Chatterjee Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
Ref No: 1228